Ozempic Lawsuit Update – April 2024

Ozempic Lawsuit Update – April 2024

In recent years, the pharmaceutical industry has faced increasing scrutiny over the safety and efficacy of various medications such as semaglutide, the active ingredient in type 2 diabetes drugs Ozempic and Mounjaro.

Demand for these drugs has skyrocketed, but not for their original treatment purpose. Taking Ozempic reduces hunger and slows stomach emptying, which often results in weight loss.

While the U.S. Food and Drug Administration (FDA) has not approved Ozempic for weight loss, many doctors have prescribed Ozempic to patients to help them lose weight—this is known as “off label use”.

As of the publication of this blog, Wegovy is the only semaglutide injection to receive FDA approval as a weight loss treatment.

However, concerns have arisen regarding potential side effects, including stomach paralysis, or gastroparesis, leading to a wave of lawsuits against Novo Nordisk, the manufacturer of Ozempic.

August 2023: The First Ozempic Stomach Paralysis Lawsuit

The first Ozempic stomach paralysis lawsuit was filed in Louisiana in August 2023.

The plaintiff, Jaclyn Bjorklund, experienced severe stomach pain and was rushed to the hospital, where she suffered a medical emergency due to the side effects of using Ozempic and Mounjaro.

She filed a lawsuit against Novo Nordisk, alleging that the maker of Ozempic failed to adequately warn patients about the drug’s more serious side effects, like stomach paralysis and intestinal blockage.

Since then, the number of Ozempic lawsuits has only increased—and we expect to continue to see the numbers rise.

February 2024: Ozempic Case Consolidation Approved

In February 2024, the U.S. Judicial Panel on Multidistrict Litigation decided to consolidate all federal Ozempic lawsuits into one multidistrict litigation (MDL).

This MDL, located in Philadelphia, Pennsylvania, will centralize pretrial proceedings for all federal lawsuits involving allegations of stomach paralysis or other serious side effects of Ozempic and similar drugs, including:

  • Mounjaro
  • Wegovy

The MDL also opens up the possibility of legal action against Eli Lilly, the manufacturer of Mounjaro, Ozempic, and Wegovy are both Novo Nordisk products.

Why Does This Ozempic Lawsuit Update Matter?

The consolidation of these cases into an MDL serves several important purposes.

Faster Resolution

First and foremost, it streamlines the legal process by centralizing pretrial proceedings such as discovery, motion practice, and expert testimony. This efficiency can lead to quicker resolutions for plaintiffs seeking justice and compensation for their injuries.

By consolidating cases, the judicial system can avoid duplicative efforts and streamline the use of court resources. This efficiency benefits not only the parties directly involved but also the broader legal system, allowing it to handle complex litigation more effectively.

Consistent Decisions

Additionally, MDLs often promote consistency in legal decisions. 

With multiple lawsuits involving similar claims, having one judge oversee the pretrial phase can help ensure that rulings are uniform and fair across all cases. This consistency is crucial in complex litigation involving pharmaceutical products and can benefit both plaintiffs and defendants by providing clarity and predictability.

Shared Resources

For plaintiffs pursuing Ozempic lawsuits, the creation of an MDL offers a clear path forward. They can benefit from collective action, shared resources, and the expertise of legal professionals specializing in pharmaceutical litigation.

This consolidation empowers plaintiffs to pursue their claims more efficiently and effectively, increasing their chances of a favorable outcome.

How Does This Affect Novo Nordisk?

On the other hand, defendants such as Novo Nordisk and Eli Lily will also benefit from MDL consolidation. 

While facing multiple lawsuits can be challenging, having a centralized process can help them manage their defense strategies more cohesively. This structured approach can lead to fair and equitable resolutions for all parties involved.

How Does This Affect Individual Ozempic Side Effects Lawsuits?

It’s important to note that the establishment of an MDL does not determine the outcome of individual cases for the plaintiffs in Ozempic lawsuits.

Every Ozempic lawsuit will still be evaluated on its merits, with evidence and legal arguments playing a crucial role in the final decisions.

However, MDL consolidation provides a framework that streamlines the legal process and promotes efficiency and fairness.


In conclusion, the consolidation of Ozempic lawsuits into a multidistrict litigation marks a significant development in the quest for justice for those who have suffered harm from the medication.

This consolidation streamlines the legal process, promotes consistency, conserves resources, and provides a structured framework for resolving complex pharmaceutical litigation.

As these cases move forward, both plaintiffs and defendants can navigate the legal landscape with greater clarity and confidence, paving the way for fair and equitable outcomes.

File an Ozempic Lawsuit

If you or a loved one is suffering from stomach paralysis or other serious health issues due to Ozempic or similar drugs, you may be able to file a lawsuit.

GB Law’s Ozempic lawyers can help. Contact us today for a free consultation and find out if you qualify for an Ozempic lawsuit.